Inactive Instrument

Intellipharmaceutics International Inc. Stock Toronto S.E.

IPCI.H

CA4581733090

Valuation: Intellipharmaceutics International Inc.

Market Cap	1.28M 1.13M 1.05M 960K 1.8M 123M 1.83M 12.43M 4.86M 60.66M 4.81M 4.71M 210M	P/E 2021	-0.4x	P/E 2022	-0.91x
Enterprise Value	3.52M 3.09M 2.88M 2.64M 4.96M 339M 5.04M 34.18M 13.35M 167M 13.23M 12.94M 577M	EV / Sales 2021	-	EV / Sales 2022	74x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	2007-03-31
Christian Akyempon PRN	Corporate Officer/Principal	-	2014-01-31

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	2004-08-31

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	-.--%	-11.11%	-	-	1.52M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+161.40%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.79%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+83.13%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+30.00%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+39.80%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.19%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-41.29%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.81%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.43%	161B
Average	+0.44%	+1.33%	+26.20%	+52.36%	404.78B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+78.15%

	2021	2022
Net sales	-	65.73K 57.73K 53.69K 49.26K 92.56K 6.33M 93.99K 638K 249K 3.11M 247K 241K 10.76M
Net income	-5.15M -4.52M -4.2M -3.86M -7.25M -495M -7.36M -49.9M -19.5M -244M -19.31M -18.9M -842M	-2.89M -2.54M -2.36M -2.17M -4.07M -279M -4.14M -28.05M -10.96M -137M -10.86M -10.62M -473M
Net Debt	1.15M 1.01M 936K 859K 1.61M 110M 1.64M 11.11M 4.34M 54.23M 4.3M 4.21M 188M	2.24M 1.97M 1.83M 1.68M 3.16M 216M 3.21M 21.75M 8.5M 106M 8.42M 8.24M 367M

Intellipharmaceutics International Inc. Stock Toronto S.E.

Stocks

IPCI.H

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile